恆瑞醫藥(600276.SH)連續第六日下跌 股價創10個月新低
格隆匯4月16日丨近日持續下跌的恆瑞醫藥(600276.SH)今日跌勢繼續,盤中一度跌3.49%報79.31元,為連續第六日下跌,股價創2020年6月以來新低,市值跌破4300億元。消息面上,先是財政部12日發佈《中華人民共和國財政部會計信息質量檢查公吿(第四十號)》,77家藥企普遍存在使用虛假髮票套取資金體外使用等違規行為,其中有19家受到了3-5萬元不等的行政處罰,恆瑞醫藥赫然在列,被罰款5萬元。隨後,15日流出的五批集採品量目錄顯示,恆瑞醫藥有4個在銷售的注射劑品種(苯磺順阿曲庫銨、碘克沙醇、奧利沙鉑、多西他賽;對應銷售收入累計是55億元,其中碘克沙醇20億元、多西他賽15億元、苯磺順阿曲庫銨15億元、奧利沙鉑5億元)被納入第五批全國仿製藥帶量採購範圍。券商一致預測恆瑞醫藥2020年營業收入預估在280億元左右,本次集採品種佔比接近20%,這部分銷售收入面臨縮水。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.